Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP)
Andrew F Shorr, Laura A Puzniak, Pinaki Biswas, Michael S Niederman, Andrew F Shorr, Laura A Puzniak, Pinaki Biswas, Michael S Niederman
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in nosocomial pneumonia and is associated with significant morbidity and mortality. Clinical outcomes for nosocomial pneumonia are dependent on patient age, co-morbidities, severity of illness and appropriate antibiotic therapy. The objective of this secondary analysis was to identify baseline clinical variables that are associated with clinical success at the end of the study observation period. Data from a randomized blinded trial (NCT00084266) comparing linezolid (600-mg twice daily) to vancomycin (15-mg/kg twice daily, dose-adjusted) for the treatment of culture-proven MRSA pneumonia were analyzed to evaluate baseline clinical and demographic factors that may predict clinical success at end of study (EOS) (7-30 days after end of treatment). A multivariate logistic regression was conducted to identify baseline factors that are associated with clinical success. Patients treated with linezolid (OR 1.55 95% CI: 1.013, 2.355), no vasopressor receipt (OR 2.30, 95% CI: 1.303, 4.069), unilateral involvement (OR 1.70, 95% CI: 1.078, 2.681) and normal renal function (eGFR 30-80 vs >80 OR 0.48, 95% CI: 0.303, 0.750) were more likely to have clinical success. From a clinical standpoint, identifying reliable predictors of outcome and who might benefit more from one therapy versus another can help inform treatment decisions.
Conflict of interest statement
Competing Interests: This study was sponsored by Pfizer Inc. AS and MSN. did not receive financial compensation in connection with the study. AS has served as a speaker, investigator, or consultant for: AZ, Astellas, Bayer, Cubist, Pfizer, Tetraphase, and Theravance. MSN has been a consultant to Pfizer, Theravance, Cubist and Sanofi Aventis and has received research support from Bayer and Cubist. LAP. was an employee of Pfizer, Inc. when this study was undertaken. PB is an employee and stockholder of Pfizer, Inc. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008; 1;46 Suppl 5:S378–85. 10.1086/533594
- Haque NZ, Arshad S, Peyrani P, Ford KD, Perri MB, Jacobsen G, et al. Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology 2012;50(5):1640–4. 10.1128/JCM.06701-11
- Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Medicine 2004;30(3):388–94.
- Wunderink RG, Niederman MS, Chastre JE, Shorr AF, Kollef MH, Reisman AL, et al. Predictors of clinical failure and mortality among patients with methicillin resistant Staphyloccous aureus (MRSA) hospital-acquired pneumonia. Am J Respir Crit Care Med. 2011;183:A3921.
- Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012; 1;54(5):621–9.
- Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine 1996; 28;15(4):361–87.
- Austin PC. Using the bootstrap to improve estimation and confidence intervals for regression coefficients selected using backwards variable elimination. Statistics in Medicine 2008; 30;27(17):3286–300.
- Lahey T. Questionable superiority of linezolid for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: watch where you step. Clin Infect Dis. 2012;55(1):159–160. 10.1093/cid/cis329
- Masuta K, Oba Y, Iwata K. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: controversy continues. Clin Infect Dis. 2012;55(1):161.
Source: PubMed